Jazz Pharmaceuticals PLC $JAZZ Shares Newly Purchased by Ethic Inc.

Posted by Geri Gentry on Nov 14th, 2026

Ethic Inc. bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 5,463 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,265,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth approximately $32,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $47,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $61,000. Finally, Elevation Wealth Partners LLC grew its position in Jazz Pharmaceuticals by 156.4% in the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 158 shares during the period. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of a number of analyst reports. Barclays lifted their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Piper Sandler increased their price objective on Jazz Pharmaceuticals from $310.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday. Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Finally, Robert W. Baird upped their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

Get Our Latest Report on JAZZ

Jazz Pharmaceuticals Stock Up 0.5%

Jazz Pharmaceuticals stock opened at $241.55 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $139.26 and a twelve month high of $266.38. The firm has a 50 day moving average price of $229.13 and a 200-day moving average price of $219.62. The company has a market capitalization of $15.51 billion, a P/E ratio of 21.31, a P/E/G ratio of 0.44 and a beta of 0.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the prior year, the business earned $8.13 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 1,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total transaction of $225,370.00. Following the sale, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. The trade was a 0.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 171,342 shares of company stock valued at $41,420,491. 4.10% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.